---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-160031"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:40:41.777054+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zymeworks reports 41.3% cORR for zanidatamab in HER2-amplified BTC from Phase 2b trial

## Summary
- cORR of 41.3% (95% CI: 30.4-52.8) in Cohort 1 (IHC 2+/3+) by independent central review.
- Median duration of response 12.9 months; median progression-free survival 5.5 months.
- 48.5% of responders had ongoing responses at October 10, 2022 data cutoff.
- Only 2.3% of patients discontinued treatment due to adverse events; no Grade 4 or treatment-related deaths.
- Data presented at ASCO 2023 and concurrently published in The Lancet Oncology.

## SEC filing metadata
- accession: 0001193125-23-160031
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312523160031/0001193125-23-160031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312523160031/d504484d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-160031
- JSON: https://secwatch.observer/filing/0001193125-23-160031.json
- Plain text: https://secwatch.observer/filing/0001193125-23-160031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.